Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05117632
Other study ID # ALTO-100-001
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date December 20, 2021
Est. completion date December 9, 2022

Study information

Verified date November 2023
Source Alto Neuroscience
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to collect biologically based data for defining predictors and correlates of the effects of ALTO-100.


Recruitment information / eligibility

Status Completed
Enrollment 245
Est. completion date December 9, 2022
Est. primary completion date December 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 69 Years
Eligibility Inclusion Criteria: - Have a diagnosis of moderate to severe major depressive disorder (MDD) and/or post-traumatic stress disorder (PTSD) - At baseline, either not taking an antidepressant medication, or currently taking a SSRI, SNRI, mirtazapine, or bupropion for at least 6 weeks with no dose modifications in the past 2 weeks - Willing to comply with all study assessments and procedures - Must not be pregnant or breastfeeding at time of enrollment or throughout study Exclusion Criteria: - Evidence of unstable cardiovascular, respiratory, liver, or renal impairment or disease - Active suicidal ideation - Diagnosed bipolar disorder, psychotic disorder, or dementia - Current moderate or severe substance use disorder - Has a history of hypersensitivity or allergic reaction to ALTO-100 or any of its components/excipients - Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device

Study Design


Intervention

Drug:
ALTO-100 PO tablet
one tablet twice daily

Locations

Country Name City State
United States Site 151 Baltimore Maryland
United States Site 109 Belmont Massachusetts
United States Site 150 Boca Raton Florida
United States Site 141 Costa Mesa California
United States Site 112 Doral Florida
United States Site 121 Draper Utah
United States Site 155 Elgin Illinois
United States Site 147 Fort Worth Texas
United States Site 148 Fort Worth Texas
United States Site 118 Fresno California
United States Site 113 Houston Texas
United States Site 120 Houston Texas
United States Site 108 Jackson Mississippi
United States Site 144 Las Vegas Nevada
United States Site 142 Lincoln Nebraska
United States Site 139 Little Rock Arkansas
United States Site 116 Martinez California
United States Site 116 Mather California
United States Site 146 Middleburg Heights Ohio
United States Site 137 Noblesville Indiana
United States Site 105 Seattle Washington
United States NTC Seattle (105a) Tacoma Washington
United States Site 136 Tempe Arizona

Sponsors (1)

Lead Sponsor Collaborator
Alto Neuroscience

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To understand the relationship between baseline biology and clinical outcome with ALTO-100 using the Montgomery-Åsberg Depression Rating Scale (MADRS) The Montgomery-Åsberg Depression Rating Scale (MADRS) measures the severity of depression where smaller scores indicate less depression and higher scores suggest more severe depression. Possible scores for this 10 item version range from 0 to 60. The change from baseline to the end of the study is the primary outcome. Measured 5 times over 8 weeks
Primary To understand the relationship between baseline biology and clinical outcome with ALTO-100 using the Clinical Global Impression scale - Severity (CGI-S) The Clinical Global Impression scale - Severity (CGI-S) measures the severity of psychopathology in general where smaller scores indicate less illness and higher scores suggest more severe illness. Possible scores for this scale range from 1 to 7. The change from baseline to the end of the study is the primary outcome. Measured 5 times over 8 weeks
Primary To understand the relationship between baseline biology and clinical outcome with ALTO-100 using the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) measures the severity of PTSD where smaller scores indicate less severe PTSD and higher scores suggest more severe PTSD. Possible scores for this 30 item version range from 0 to 120. The change from baseline to the end of the study is the primary outcome. Measured 3 times over 8 weeks
Primary Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability of ALTO-100 An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. From the signing of the ICF until the follow-up visit (up to 12 weeks)
Primary Number of Participants With Clinically Significant Vital Signs Abnormalities as a Measure of Safety and Tolerability of ALTO-100 Vital signs measured include blood pressure, heart rate, respiratory rate, temperature, and weight. From the signing of the ICF until the end-of-treatment visit (up to 11 weeks)
Primary Number of Participants With Clinically Significant Laboratory Abnormalities as a Measure of Safety and Tolerability of ALTO-100 Blood samples for serum chemistry and hematology will be collected for clinical laboratory testing. From the signing of the ICF until the end-of-treatment visit (up to 11 weeks)
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4